The article also covers significant business moves, such as AstraZeneca's acquisition of EsoBiotec and Hologen AI's joint venture with MeiraGTx. It touches on the challenges of using AI to predict epidemics, emphasizing the need for better data systems and benchmarks for AI model performance. Other notable developments include LabCorp's acquisition of BioReference's cancer business, the impact of abortion bans on talent recruitment, and Purdue Pharma's new bankruptcy plan. The article concludes with various public health concerns, including the measles outbreak in Texas and the potential rise in HIV infections among infants due to funding cuts.
Key takeaways:
- Policy uncertainty around vaccines is causing mixed messages from the HHS and White House, affecting vaccine market stability and uptake levels.
- Women experience more side effects than men from GLP-1 drugs, with research suggesting hormonal cycles and receptor expression differences as potential causes.
- AstraZeneca is acquiring Belgian biotech company EsoBiotec to advance cell therapies for cancer treatment, with a deal potentially worth up to $1 billion.
- AI's potential in predicting epidemics is hindered by fragmented data systems, and clear benchmarks are needed to assess AI model performance in public health.